Intramural Funding Opportunities
Aug 21 - Sep 21: Resource Allocation Program (RAP) Fall 2020 Cycle
The UCSF Resource Allocation Program (RAP) offers a single online application process for a variety of intramural grants. Applications will open August 21.
LOI Deadline: July 30
Department of Defense (DoD) FY20 Peer Reviewed Cancer Research Program
- Virtual Cancer Center – Director Award
- Virtual Cancer Center – Career Development Award (Scholar Option)
- Career Development Award (Fellow Option)
- Behavioral Health Science Award
- Translational Team Science Award
Deadline: Aug 12
NCCN/Pfizer Request for Proposals (RFP) Phase I/II Clinical Trials of Axitinib in the Treatment of Melanoma, Hepatocellular Carcinoma and Colorectal Cancer
NCCN in collaboration with Pfizer Global Medical Grants (Pfizer) offers a new grant opportunity that will support NCCN Member Institution faculty in studies of axitinib. The intent of this RFP is to encourage NCCN Member Institutions to submit clinical research proposals specifically in the treatment of melanoma, hepatocellular carcinoma (HCC) and colorectal cancer (CRC).
LOI Deadline: Aug 13
ACS-Pfizer Prostate Cancer Disparities Project Competitive Grant Program
The American Cancer Society and Pfizer Global Medical Grants are collaborating to offer a new competitive grant opportunity focused on addressing prostate cancer disparities impacting Black men.
LOI Deadline: Sep 1
SU2C Health Equity Breakthrough Team Research Grant Program
The Breakthrough Team represents an unprecedented opportunity to bring together the best scientific minds from diverse fields of research to concentrate on new approaches to address health equity in the context of cancer research.
LOI Deadline: Sep 9
NCCN/Pfizer Request for Proposals (RFP) Adoption of Biosimilars in Oncology
The National Comprehensive Cancer Network® (NCCN) and Pfizer Global Medical Grants (Pfizer) are collaborating to offer a new grant opportunity seeking proposals in support of the adoption of biosimilars in oncology. Seeking proposals describing concepts and ideas that develop and validate enduring approaches that improve the safe and efficient adoption of biosimilars in oncology. Proposals that directly measure increases in biosimilar use or improve safety, value and efficiency in oncology practices will be prioritized. The sustainability and broad applicability of the approach will be key factors in evaluating funded projects.
Deadline: Aug 14, 2020
National Cancer Institute (NCI) Emergency Administrative Supplements for Research and Training Continuity of Postdoctoral Fellows during Coronavirus Disease 2019 (COVID-19) NOT-CA-20-082
Deadline: Sep 25, 2020
To view all NCI funding opportunities, search here